Managing respiratory symptoms at the end of life

Clinics in Geriatric Medicine

Volumn 19, Issue 1, 2003, Pages 225-239

  Jacobs, Laurie G ^a,b  

^a ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

^b MONTEFIORE MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AGED; COUGHING; DYSPNEA; ELDERLY CARE; HICCUP; HUMAN; PALLIATIVE THERAPY; RESPIRATORY TRACT DISEASE; REVIEW; SYMPTOMATOLOGY; TERMINAL CARE; TERMINAL DISEASE; TREATMENT PLANNING;

AGE FACTORS; AGED; CAUSALITY; CHRONIC DISEASE; COST-BENEFIT ANALYSIS; DYSPNEA; HUMANS; RESPIRATION, ARTIFICIAL; TERMINAL CARE; TREATMENT OUTCOME;

EID: 0037290968     PISSN: 07490690     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0749-0690(02)00054-X     Document Type: Review

References (61)

1. Reuben DB, Mor V. Dyspnea in terminally ill cancer patients. Chest 1986;89:234-6.
2. American Thoracic Society. Dyspnea. Mechanisms, assessment and management: A consensus statement. Am J Respir Crit Care Med 1999;159:321-40.
3. The SUPPORT Principal Investigators. A controlled trial to improve care for seriously ill hospitalized patients. The study to understand prognoses and preferences for outcomes and risks of treatments (SUPPORT). JAMA 1995;274:1591-8.
4. Lynn J, Teno J, Phillips R, et al. Perceptions by family members of the dying experience of older and seriously ill patients. Ann Intern Med 1997;126:97-106.
5. Mercadante S, Casuccio A, Fulfaro F. The course of symptom frequency and intensity in advanced cancer patients followed at home. J Pain Symptom Manage 2000;20:104-12.
6. Bruera E, Schmitz B, Pither J, et al. The frequency and correlates of dyspnea in patients with advanced cancer. J Pain Symptom Manage 2000;19:357-62.
7. Larson DG, Tobin DR. End-of-life conversations: Evolving practice and theory. JAMA 2000;284:1573-8.
8. Hinton J. An assessment of open communication between people with terminal cancer, caring relatives, and others during home care. J Palliat Care 1998;14:15-23.
9. Quill TE. Initiating end-of-life discussions with seriously ill patients. Addressing the "elephant in the room." JAMA 2000;284:2502-7.
10. Luce JM, Luce JA. Management of dyspnea in patients with far-advanced lung disease. "Once I lose it, it's kind of hard to catch it. . ." JAMA 2001;285:1331-7.
11. Fox E, Landrum-McNiff K, Zhong Z, et al. Evaluation of prognostic criteria for determining hospice eligibility in patients with advanced lung, heart or liver disease. JAMA 1999;282:1638-45.
12. Connors AF, Dawson NV, Thomas C, et al. Outcomes following acute exacerbation of severe chronic obstructive lung disease. Am J Respir Crit Care Med 1996;154:959-67.
13. Meisel A, Snyder L, Quill T. Seven legal barriers to end-of-life care. Myths, realities, and grains of truth. JAMA 2000;284:2495-501.
14. Lynn J, Ely EW, Zhong Z, et al. Living and dying with chronic obstructive pulmonary disease. J Am Geriatr Soc 2000;48:S91-S100.
15. Kikuchi Y, Okabe S, Tamura G, et al. Chemosensitivity and perception of dyspnea in patients with a history of near-fatal asthma. N Engl J Med 1994;330:1329-34.
16. Lane R, Adams L. Metabolic acidosis and breathlessness during exercise and hypercapnia in man. J Physiol 1993;461:47-61.
17. Dudgeon D, Lertzman M. Dyspnea in the advanced cancer patient. J Pain Symptom Manage 1998;16:212-9.
18. Jefia R, Ward J, Lentine T, Mahler DA. Target dyspnea ratings predict expected oxygen consumption as well as target heart rate values. Am J Respir Crit Care Med 1999;159:1485-9.
19. Aaronson N, Bullinger M, Ahmedzai S. A modular approach to quality of life assessment in cancer clinical trials. Cancer Res 1988;111:231-49.
20. Guyatt GH, Berman LB, Townsend M, et al. A measure of quality of life for clinical trials in chronic lung disease. Thorax 1987;42:773-8.
21. Ahmedzai S. Palliation of respiratory symptoms. In: Doyle D, Hanks GWC, MacDonald N, editors. Oxford Textbook of Palliative Medicine, 2nd Edition. Oxford: Oxford University Press; 1998. p. 583-616.
22. Bartter T, Akers SM, Pratter MR. The evaluation of pleural effusion. Chest 1994;106:1209-14.
23. Gryminski J, Krakowda P, Lypacewicz G. The diagnosis of pleural effusion by ultrasonic and radiologic techniques. Chest 1976;70:33-7.
24. Estenne M, Yernault JC, Troyer A. Mechanism of relief of dyspnea after thoracentesis in patients with large pleural effusions. Am J Med 1983;74:813-9.
25. Rodriquez-Panadero F, Lopez-Mejias J. Survival time of patients with pleural metastatic carcinoma predicted by glucose and pH studies. Chest 1989;95:320-4.
26. Sahn SA, Good JT. Pleural fluid pH in malignant effusions. Ann Intern Med 1988;108:345-9.
27. Nocturnal Oxygen Therapy Trial Group. Continuous or nocturnal oxygen therapy in hypoxemic chronic obstructive lung disease: A clinical trial. Ann Intern Med 1980;93:391-8.
28. The Medical Research Council Working Party. Long-term domiciliary oxygen therapy in chronic hypoxic cor pulmonale complicating chronic bronchitis and emphysema. Lancet 1981;1:681-5.
29. Heaton RK, Grant I, McSweeney AJ, et al. Psychologic effects of continuous and nocturnal oxygen therapy in hypoxemic chronic obstructive pulmonary disease. Arch Intern Med 1983;143:1941-7.
30. Petty TL, Finigan MM. Clinical evaluation of prolonged ambulatory oxygen therapy in chronic airway obstruction. Am J Med 1968;45:242-52.
31. Bruera E, de Stoutz N, Velasco-Leiva A, et al. Effects of oxygen on dyspnoea in hypoxaemic terminal-cancer patients. Lancet 1993;342:13-4.
32. Booth S, Kelly MJ, Cox MP, et al. Does oxygen help dyspnoea in patients with cancer? Am Rev Resp Crit Care Med 1996;153:1515-8.
33. Dewan NA, Bell CW. Effect of low flow and high flow oxygen delivery on exercise tolerance and sensation of dyspnea: A study comparing the transtracheal catheter and nasal prongs. Chest 1994;105:1061-5.
34. Light RW, Muro JR, Sato RI, et al. Effects of oral morphine on breathlessness and exercise tolerance in patients with chronic obstructive pulmonary disease. Am J Respir Dis 1989;139:126-33.
35. Vacco v Quill, 117 S.Ct. 606 (1997).
36. Washington v Glucksberg, 117 S.Ct. 735 (1997).
37. Luce JM, Alpers A. Legal aspects of withholding and withdrawing life support from critically ill patients in the United States and providing palliative care to them. Am J Respir Crit Care Med 2000;162:2029-32.
38. Bruera E, MacEachem T, Ripamonti C, et al. Subcutaneous morphine for dyspnea in cancer patients. Ann Intern Med 1993;119:906-7.
39. Cohen MH, Anderson AJ, Krasnow SH, et al. Continuous intravenous infusion of morphine for severe dyspnea. South Med J 1991;84:229-34.
40. Noseda A, Carpiaux J-P, Markstine C, et al. Disabling dyspnoea in patients with advanced disease: Lack of effect of nebulized morphine. Eur Respir J 1997;10:1079-83.
41. Young IH, Daviskas E, Keena VA. Effect of low dose nebulized morphine on exercise endurance in patients with chronic lung disease. Thorax 1989;44:387-90.
42. Poole PJ, Veale AG, Black PN. The effect of sustained-release morphine on breathlessness and quality of life in severe chronic obstructive pulmonary disease. Am J Respir Crit Care Med 1998;157:1877-80.
43. Man GCW, Hsu K, Sproule BJ. The effect of alprazolam on exercise and dyspnea in patients with chronic obstructive pulmonary disease. Chest 1986;9:832-6.
44. Barach AL. Chronic obstructive pulmonary disease: Postural relief of dyspnea. Arch Phys Med Rehabil 1974;55:494-503.
45. O'Neil S, McCarthy DS. Postural relief of dyspnea in severe chronic airflow limitation: Relationship to respiratory muscle strength. Thorax 1983;38:585-600.
46. Pan CX, Morrison RS, Ness J, et al. Complementary and alternative medicine in the management of pain, dyspnea, and nausea and vomiting near the end of life: A systematic review. J Pain Symptom Manage 2000;20:374-87.
47. Jobst K, Chen JH, McPherson J, et al. Controlled trial of acupuncture for disabling breathlessness. Lancet 1986;2:1416-8.
48. Filshie J, Penn K, Ashley S, et al. Acupuncture for the relief of cancer related breathlessness. Palliat Med 1996;10:145-50.
49. Cristiano LM, Schwartzstein RM. Effect of chest wall vibration on dyspnea during hypercapnia and exercise in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 1997;155:1552-9.
50. Renfroe KL. Effect of progressive relaxation on dyspnea and state anxiety in patients with chronic obstructive pulmonary disease. Heart Lung 1988;17:408-13.
51. Corner J, Plant H, A'Hern R, Bailey C. Non-pharmacological intervention for breathlessness in lung cancer. Palliat Med 1996;10:299-305.
52. Friedman LS, Isselbacher KJ. Nausea, vomiting, and indigestion. In: Fauci AS, Braunwald E, Isselbacher KJ, et al, editors. Harrison's Principles of Internal Medicine. 14th Edition. New York: McGraw-Hill; 1998. p. 230-6.
53. Tune LE. Anticholinergic effects of medication in elderly patients. J Clin Psychiatry 2001;62 (Suppl 21):11-4.
54. Ramirez FC, Graham DY. Treatment of intractable hiccup with baclofen: Results of a doubleblind randomized, controlled crossover study. Am J Gastro 1992;87:1789-91.
55. Mukhopadhyay P, Osman MR, Wajima T, Wallace TI. Nifedipine for intractable hiccups. N Engl J Med 1986;314:1256.
56. Lipps DC, Jabbari B, Mitchell MH, Daigh JD. Nifedipine for intractable hiccups. Neurology 1990;40:531-2.
57. Ives TJ, Fleming MF, Weart CW, Block D. Treatment of intractable hiccups with intramuscular haloperidol. Am J Psych 1985;142:1368-9.
58. Bergman B, Aaronson NK, Ahmedzai S, et al. The EORTC QLQ-LC13: A modular supplement to the EORTC core quality of life questionnaire (QLQ-C30) for use in lung cancer clinical trials. Eur J of Ca 1994;30A:635-42.
59. Bruera E, Macmillan K, Pither J, MacDonald RN. Effects of morphine on the dyspnea of terminal cancer patients. J Pain Symptom Manage 1990;5:341-4.
60. Maa SH, Gauthier D, Turner M. Acupressure as an adjunct to a pulmonary rehabilitation program. J Cardiopulm Rehab 1997;17:268-76.
61. Rosser R, Denford J, Heslop A, et al. Breathlessness and psychiatric morbidity in chronic bronchitis and emphysema: A study of psychotherapeutic management. Psychol Med 1983;13:93-110.